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Abstract
Background: In unipolar, and bipolar affective disorders, there is a high risk of relapse that increases as the
number of episodes increases. Naturalistic follow-up studies suggest that the progressive development of the
diseases is not prevented with the present treatment modalities. It is not known whether centralised and
specialised secondary care intervention initiated early after the onset of the diseases can prevent the progression
and thereby improve the prognosis.
Methods: Two randomised clinical multi-centre trials comparing a centralised and specialised outpatient
intervention program consisting of combined pharmacological and psychological intervention with standard
decentralised psychiatric treatment. Patients discharged from their first, second, or third hospitalisation due to a
manic episode or bipolar disorder (trial 1) or to a single depressive episode or recurrent depressive disorder (trial 2)
were randomised. Central randomisations for both trials were stratified for the number of hospitalisations and
treatment centre. The primary outcome measure for the two trials is time to re-hospitalisation with an affective
episode.
Discussion: These trials are the first to evaluate the effect of a centralised and specialised intervention in patients
with early severe affective disorders. The trials used a pragmatic design comparing a specialised mood disorder
clinic intervention with decentralised, non-specialised standard psychiatric treatment.
Trial Registration: ClinicalTrials.gov: NCT00253071
Background and objective
Background
Affective disorders are associated with a high risk of
relapse and the risk of relapse increases as the number
of previous episodes increases [1,2]. Many patients do
not recover to previous psychosocial function [3,4].
A proportion of patients present with cognitive impair-
ment also during the remitted phase [5-7], and the risk
of developing dementia seems increased in the long run
[8,9]. It is well documented from randomised clinical
trials that the risk of a new episode in bipolar disorder
can be reduced significantly by treatment with lithium
or other mood stabilizers [10]. In unipolar disorder con-
tinued treatment with antidepressants significantly
reduces the risk of relapse [11]. Further, the prophylac-
tic effect of medical treatment may be enhanced by
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bipolar disorder [12-17] and by cognitive behavioural
therapy in unipolar disorder [18-20]. However, results
from naturalistic follow up studies suggest that the pro-
gressive development of the diseases is not prevented in
clinical practice with the present treatments [21-23].
Part of the explanation may be decreased adherence
with mood stabilizers and antidepressants, [24-29] but
another explanations may be delayed intervention -
pharmacologically and psychologically. Results from a
number of studies comparing specialist first episode
anti-psychosis programs versus standard treatment have
shown that there are positive effects of early and sus-
tained intervention following the first psychotic episode
[30]. Within affective disorders, a number of studies
have investigated the effect of health-service interven-
tions in bipolar disorder [31-35] and recurrent depres-
sive disorder [36-41]. However, to the best of our
knowledge, no randomised clinical trial has investigated
the effects of centralised and specialised combined phar-
macological and psychological intervention in the early
phases of unipolar or bipolar disorders. There are indir-
ect suggestions that early intervention may improve the
course and outcome in affective disorders. As sum-
marised by Berk et al. [42], lithium for instance may be
less effective in bipolar disorder as well as in unipolar
disorder if not initiated early [43-45] although not all
studies confirm this finding [46,47]. Further, response to
cognitive behavioural therapy (CBT, [48]) and to psy-
choeducation [49] may be more effective when used
during the early course of illnesses than after a dozen
illness episodes, although a meta-analysis showed no
clear evidence that the numbers of episodes moderate
the effect of psychological therapy [50]. In addition,
brain imaging data suggest that cognitive decline and
reduction in brain volume are linked to recurrences [51]
and cognitive dysfunction may increase with increasing
numbers of episodes [52]. Finally, lithium and other
mood stabilizers may have protective effects decreasing
the tendency to cognitive decline [53-57] but existing
data does not lead to any definite conclusion of a neuro-
protective effect of long-term lithium therapy. Similarly,
data do suggest that maintenance antidepressants pre-
scribed for unipolar depressive disorder may have neu-
roprotective abilities but this is not definitive either
[58,59].
It is likely that affective disorder patients are more
able to benefit from medication, psychoeducation, cog-
nitive behavioural therapy, or any other intervention if
the intervention takes place early during the course of
illness before a decline in psychosocial or cognitive
function becomes manifest [42]. There are several diffi-
culties in studying the effect of early intervention in
affective disorders in general and bipolar disorder in
specific [60]. The specificity of prodromal symptoms of
the first episode is unknown and even when patients
have had several episodes there is a delay of referral to
treatment that prolongs time to accurate diagnosis and
treatment [61]. In the present trials we focused on
patients with severe affective disorders who were hospi-
talised for an affective episode. We only included
patients after the first, second, or third time of hospitali-
sation. The present paper presents the background,
hypotheses, design, outcomes, and statistical analyses of
the two trials.
Hypotheses
Based on the literature we hypothesised that centralised
and specialised outpatient intervention of patients early
in the course of severe affective disorder:
1) decreases the risk of re-admission to a psychiatric
hospital;
2) decreases the risk of relapse of new affective
episodes;
3) increases adherence with medical treatment;
4) increases quality of life; and
5) increases satisfaction with treatment
compared with decentralised, non-specialised psychia-
tric outpatient treatment.
Objective
The aim of the present trials is to investigate whether
centralised and specialised outpatient secondary care
intervention for patients with severe affective disorder
improve prognosis compared with standard psychiatric
outpatient treatment in patients early in the course of
mania/bipolar disorder (trial I) or depression/recurrent
depressive disorder (trial II). The trials are naturalistic
with very few exclusion criteria and investigate the effect
among patients following psychiatric hospitalisation in
The Capital Region of Denmark. When hospitalised
patients were diagnosed and treated by the clinicians
employed at the hospital. This pragmatic design was
chosen to obtain a high generalisability of results from
the trials to clinical settings regarding patients with the
most severe affective disorders [62].
Methods
Study design
Patients were included from seven out of the nine psy-
chiatric wards in The Capital Region of Denmark.
Participants and screening
According to the sample size calculation, it was planned
to randomise a total of 180 patients with a manic epi-
sode/bipolar disorder (trial I) and 260 patients with a
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(trial II) to outpatient intervention in a centralised and
specialised mood disorder clinic versus standard outpati-
ent treatment. Patients in the experimental group were
offered intervention in the mood disorder clinic consist-
ing of a combination of psychopharmacological and psy-
chological intervention and social intervention.
Randomisation
Patients were randomised to the intervention group or
the control group at the end of the index hospitalisation.
Randomisation was conducted centrally by the Copen-
hagen Trial Unit according to a computer generated
allocation sequence to secure allocation concealment. In
this way randomisation was independent of the profes-
sionals delivering treatment. The ratio of randomisation
between the intervention and the control group was 1:1.
Randomisation was stratified according to two variables:
1) psychiatric centres and 2) number of previous psy-
chiatric hospitalisations (0, 1, or 2). The randomisations
were carried out with varying block sizes unknown to
the site investigators.
Inclusion and exclusion criteria
Inclusion criteria: Patients discharged from their first,
second or third hospitalisation from a psychiatric ward
with an ICD-10 diagnosis of a manic episode or bipolar
disorder (ICD-10 code: DF30-31.9) or a single moderate
or severe depressive episode or recurrent depressive dis-
order (ICD-10 code: DF32.1-33.9) as the primary diag-
nosis. Comorbidity with alcohol or substance abuse and
other psychiatric disorders were allowed. The patients
were diagnosed by the medical doctor at the local psy-
chiatric ward. Age was between 18 and 70 year old. The
patients were able and willing to give written and oral
informed content.
Exclusion criteria: Patients with moderate or severe
dementia. Patients with poor understanding of Danish
language. Patients under any kind of psychiatric invo-
luntary commitment.
Blinding
Blinding of patients and the treating clinicians was not
possible as patients were randomised to the mood disor-
der clinic or to standard treatment. Nevertheless, statis-
tical analyses and the writing of the scientific paper
including introduction and results will be carried out
before data are unblinded.
The mood disorder clinic
Patients in the intervention group were treated in a specia-
lised outpatient mood disorder clinic at Psychiatric Centre
Copenhagen, Rigshospitalet, Copenhagen University
Hospital. The clinic was established September 2004 in
parallel to the work and publication of a Health Technol-
ogy Assessment (HTA) report on outpatient treatment in
severe affective disorders [63], chaired by the last (LVK)
and first author (HVH)). The HTA report examined the
following three key aspects of outpatient treatment of
patients with major affective disorder:
￿ Prophylactic pharmacotherapy.
￿ Prophylactic combination therapy (pharmacother-
apy and psychological intervention/psychosocial
support).
￿ Doctor-patient cooperation expressed as the degree
of adherence to the internationally recommended
treatment guidelines.
It was recommended that the current organisation of
outpatient treatment of patients with depressive or bipo-
lar affective disorder should be supplemented with 5-10
specialised clinics in Denmark and that the clinics
should:
1. be a supplement to the present decentralised
treatment;
2. provide treatment of the highest professional
standard;
3. offer both pharmacotherapy and psychological
intervention;
4. regularly perform quality assurance and quality
development of the interventions; and
5. provide education and perform research in diag-
nosis and treatment of affective disorder.
The staff in the outpatient mood disorder clinic at
Rigshospitalet, Copenhagen University Hospital consists
of full time specialists in psychiatry with specific clinical
experience and knowledge on diagnosis and treatment
of affective disorders as well as certified psychologists,
nurses and a social worker with experience within affec-
tive disorders. The staff in the mood disorder clinic did
not provide treatment to any of the patients in the stan-
dard treatment group.
Intervention group
During the first year following establishment of the
clinic a detailed intervention program including manuals
for psychological group interventions (psychoeducation
and cognitive behavioural therapy) was developed,
tested, and revised in a pilot phase with inclusion of
approximately 30 patients. The final combined pharma-
cological and non-pharmacological intervention program
was as following. Separate intervention programs are
provided for patients with bipolar disorder and patients
for unipolar disorder lasting two years for patients with
bipolar disorder (trial I) and one year for patients with
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patients who did not achieve remission during these
periods were offered further individual treatment).
According to the protocol, the physician evaluates all
patients in the clinic less than two weeks after discharge
from the local psychiatric ward. Although most patients
improve during hospitalisation for affective disorders it
is well known that they do still suffer from affective
symptoms at discharge from hospitals in the Copenha-
gen area [64]. Prior course of illness and effect of treat-
ment is carefully recorded and diagnosis and treatment
plans are re-evaluated and current pharmacological
treatment adjusted in accordance with clinical status
and the national [65,66] and international guidelines
[67-71]. Patients with a unipolar depressive disorder
were offered acute and prophylactic treatment with
ssri’s/dual action drugs depending on individual effects
and side effects. In case of poor response, switch was
made to nortriptyline and if necessary, subsequently in
combination with lithium. The main mood stabilisers
for bipolar disorder were lithium, lamotrigine and
valproate that for some patients were combined with
atypical antipsychotics (mainly olanzapine, quetiapine,
aripiprazole) or antidepressants for shorter time periods.
Decisions on patient’s individual pharmacotherapy were
made by the individual physician in accordance with the
other specialists in psychiatry and other providers at
weekly staff conferences. Prescription of medication and
adherence to medication will be characterised using the
national medication register of all medication purchased
at pharmacies in Denmark. Subsequently, the physician
follows the patients with regular appointments depend-
ing on their clinical status and needs. In addition,
patients participate in three different sequential group
sessions weekly. All sessions are carried out in accor-
dance with the manuals although individualised accord-
ing to characteristics and needs of patients in the group.
The first group is a settling-in group for patients just
discharged from hospitalisation and with focus on the
current clinical status, beliefs, and experiences in rela-
tion to the recent hospitalisation. Patients stay in this
group until they are clinically stable and in at least
partly remitted from affective symptoms (Hamilton
Depression Score-17 items <14 and Young Rating
Mania Scale <14), i.e., typically for some months up to
half a year. When stable, the patients join a second and
intermediary group consisting of either group psychoe-
ducation or cognitive behavioural therapy. The type of
group therapy is decided by the clinician and the patient
in collaboration. The group sessions consist of 11/2
hours intervention every week for 12 consecutive weeks.
In both groups, focus is on knowledge and acceptance
of suffering from an affective disorder (bipolar or unipo-
lar), identifying affective symptoms from normal
reactions, personal identity in relation to suffering from
an affective disorder, risk situations, stress management,
the need for sustained pharmacological maintenance
treatment, adverse events due to treatment, and identifi-
cation of individual prior early warning signs of upcom-
ing affective episodes. In addition, the cognitive
behavioural therapy group sessions focus on inter-indivi-
dual conflicts and cognitive distortions in identity and
behaviour. Finally, the patients join a 3-6 months train-
ing discharge group that is a preparation for re-referral
to the initially referring physician with the aim of identi-
fying individual early warning signals prospectively in
practice and training of how to change upcoming perso-
nal conflicts and cognitive distortions.
Six to eight patients and two therapists (psychiatrist,
psychologist, or nurse) participate in each group. In the
cognitive behavioural groups, at least one therapist has a
formal education in cognitive behavioural therapy.
Adherence to group treatment programmes is recorded.
Parallel to these sessions, relatives to patients with bipo-
lar disorder were offered a manual based psychoeduca-
tive group course consisting of 2-hours sessions weekly
for six weeks.
The physician directs and co-ordinates treatments and
makes decisions on discharge, in accordance with other
health-care providers.
Control group
The control group of patients were offered standard out-
patient care consisting of the standard mental health ser-
vice routines in The Capital Region of Denmark which is
rather similar across the geographical catchments areas
associated with the seven wards, i.e., treatment at the gen-
eral practitioner, a private psychiatrist, or at the commu-
nity mental health centre. Participation in the trials had no
influence on the treatment offered to these patients. Com-
pared with the intervention in the mood disorder clinic,
psychopharmacological treatment is likely to be more
based on the preferences of the individual medical physi-
cian than on national and international guidelines. Pre-
scription of medication will be characterised using the
national medication register of all medication purchased
at pharmacies in Denmark. Psychosocial treatment ele-
ments like psychoeducation and cognitive behavioural
therapy, and contact with family is in general provided
infrequently and in a less intensive, non-systematic way
and only for a minority of the control patients.
Outcome assessments
Patients in the experimental intervention group and in the
control group had been hospitalised to the same psychia-
tric departments prior to randomisation and would be
readmitted to the same department if re-hospitalisation
would be needed following randomisation.
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first re-admission to a psychiatric ward with an affective
episode. Data on re-hospitalisation will be obtained one,
two, and five years following randomisation from the
nation-wide Danish Psychiatric Central Register that
contains data on all inpatients and outpatients contacts
to all psychiatric hospital based services in Denmark
[72]. Since 1 January 1994 the ICD-10 has been in use
in the register [73].
The secondary outcome measures are 1) the develop-
ment of a depressive or manic/mixed episode of at least
moderate severity - together and separately, one and
two years after randomisation and 2) adherence to
maintenance antidepressant and mood stabilizing treat-
ments one and two years after randomisation. These
outcomes were assessed using questionnaires that were
send to all participants one and two years following
randomisation: the Major Depression Inventory (MDI)
[74-76] and the Mood Disorder Questionnaire (MDQ)
[77,78]. A depressive episode (of at least moderate
severity) is defined as the presence of two or three
depressive core symptoms and four to seven accompa-
nying symptoms on the MDI. A manic or mixed epi-
sode is defined as a score of seven or more on the
MDQ. The Antidepressant Compliance Questionnaire
and the Mood stabilizer Compliance Questionnaire
were used for measuring compliance with treatment
modified after Demyttenaere [79,80].
The tertiary outcome are satisfaction with the inter-
vention one and two years after randomisation esti-
mated by the WHO (Five) well-being index [81,82] and
the Verona Satisfaction Scale-Affective Disorder (VSS-
A) [83]. Death due to suicide will be identified using
register data from the Danish Medical Register on Vital
Statistics [84].
Psychiatric outpatient contact and use of medication
will be analysed for the intervention and control groups
using register based data. Thus, we will have complete
(register based) data on re-hospitalisation, medication
and suicide whereas questionnaire based data will be
missing for some patients who drop out of the trials.
Sample size calculation
Anticipating a hazard ratio (HR) of 0.65 in the compari-
son of the intervention group with the control group on
the primary outcome, a two-sided risk of type 1 error, a,
of 0.05, a type 2 error risk, b,o f2 0 % ,a n de q u a lg r o u p
size, the sample size (N) for trial I was calculated to N =
176 under the further assumption of a median time to
re-hospitalisation of approximately 6 months in the con-
trol group, an inclusion period on 36 months, and a fol-
low up period of 12 months. The sample size in trial II
was based on similar assumptions (see Figure 1). How-
ever, patients with unipolar depressive disorder are more
prevalent than patients with mania or bipolar disorder.
Hence, we expected to be able to randomise more
patients with unipolar depressive disorder. If we finally
accrued a higher sample size in trial II compared to trial
I, then the power for detection of a HR of 0.65 would
become higher than 80%. The required sample sizes were
calculated with the prospect of using a log rank test-
statistic to test the null-hypothesis of no difference in
time from randomisation to the primary outcome of re-
admission to psychiatric hospital.
The assumption of time to re-hospitalisation was
based on national hospital data showing that half of all
patients hospitalised with a diagnosis of depression or
mania/bipolar disorder are re-hospitalised within a few
months [85]. The assumption that the proportion of re-
admission would be 35% decreased in the intervention
group compared with the intervention group was based
on findings of the effect of psychoeducation in bipolar
disorder [86] and further on presumptions of positive
effects of the early contact to patients during the vulner-
able period following hospital discharge (less than two
weeks) and a low drop out in the intervention group as
experienced during the pilot phase of the trials.
Statistical analyses
Separate statistical analyses will be made for patients
with bipolar disorder and patients with unipolar disor-
der. The statistical analyses will be made as ‘intention-
to-treat’ analyses. Regarding the primary outcome, time
to the first re-hospitalisation will be estimated in
Kaplan-Meier plots. The difference in cumulated preva-
lence of re-hospitalisation in the intervention and in the
control group will be tested in log-rank tests. The abso-
lute and relative hazard risk reductions and the corre-
sponding 95% confidence intervals will be calculated. In
addition, hazard ratios adjusted for age, sex, psychiatric
centre, and number of previous admissions will be cal-
culated in Cox’ regression models.
Analyses comparing participants and eligible non-
participants in the trials will be carried out using data
from the Danish Central Psychiatric Register to identify
any difference between these groups regarding sex, age,
primary diagnosis, diagnoses of comorbidities, and num-
ber of previous admissions to psychiatric hospitals.
Ethical considerations
The trials are approved by the Danish Research Ethical
Committee (KF 01 272130) and the Danish Data Protec-
tion Agency (CVR-nr. 11-88-37-29). We have written
informed consent from any patients involved in the
trials, including consent to participate in the trials and
consent to publish, where appropriate. Further, the trials
are registered at http://www.clinicaltrials.gov (ID:
NCT00253071). The trial participant’s unique and
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Danish National Board of Health in order to link to
data from the Danish Central Psychiatric Register, the
Medicinal Product Statistics, and the Danish Medical
Register on Vital Statistics to the study data.
Results
Current trial status
Recruitment of bipolar patients was somewhat slower
than expected, so the recruitment period had to be
extended one year further than the originally planned
three-year inclusion period for both patient groups.
Thus, patient enrolment started in December 2005 and
closed in December 2009, resulting in enrolment and
randomisation of a total of 426 participants, 158 with
bipolar disorder and 268 with unipolar disorder.
Accordingly, we did not reach the planned number of
176 patients with bipolar affective disorder. Among uni-
polar patients, 63.1% were women and the median age
was 38.6 years (quartiles: 31.1 to 53.4). Among bipolar
patients, 54.4% were women and the median age was
35.6 years (quartiles: 27.7 to 47.1).
Power calculations for trials I and II
In the bipolar disorder trial I, the number of 158
recruited patients results in a power of 76% (power = 1-
b) for the detection or rejection of a HR of 0.65. In the
unipolar disorder trial II, the number of 268 recruited
patients results in a power of 93% for the detection or
rejection of a HR of 0.65. The power in trial I would be
60% and the power in trial II 82% to detect or reject a
HR of 0.70. The power in trial I would be 42% and the
power in trial II 63% to detect or reject a HR of 0.75.
The statistical power in the two trials is calculated with
the prospect of using a log rank test-statistic to test the
null-hypothesis of no difference in time from randomi-
sation to the primary outcome.
Discussion
Limitations
It is an inherent limitation of the trials designs that it is
not possible to blind patients and treating clinicians for
intervention due to the nature of the intervention (spe-
cialised out-patient intervention versus standard treat-
ment). This may limit the inferences based on these
trials. The trials aim to investigate the effect of specia-
lised and centralised secondary care intervention early
i nt h ec o u r s eo fs e v e r ea f f e c t i v ed i s o r d e r s ,i . e . ,i n
patients discharged from their first, second, or third
hospitalisation. It is evident that some of these patients
may have experienced prior affective episodes less severe
than those resulting in hospitalisation and there may
have been a delay in seeking help and diagnosis of the
mood disorder [45,46] as reflected in the relatively high
median age (especially for bipolar patients). Neverthe-
less, randomisation should take care of this potential
confounder in our analyses.
Further, it should be noted that the study is estimating
the effect of a complex intervention in a centralised and
specialised mood disorder clinic. The intervention con-
sists of a combination of many different elements and
we suspect it will be impossible to differentiate the
effect of the different intervention components consist-
ing of medical treatments, psychoeducation, cognitive
behavioural intervention, and social support.
The patients in the experimental intervention group
received a well-defined intervention program according
to a manual. Little is known about the treatment offered
to the patients in the control group. It is likely that the
patients in the control group received very different
Trial II 
Trial I 
Figure 1 Anticipated statistical power estimations in Trials I and II. The anticipated power in the trials on the x-axis as a function of the
sample size of the trials on the y-axis based on a = 0.05 and an anticipated hazard ratio of 0.65 and 6 month median time from randomisation
to re-admission to hospital in the control group, 48 month inclusion period, and at least a 12 month follow up of all patients.
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between a broad, competent and prolonged service to a
much shorter and sporadic offer of treatment. Further-
more, the intervention in the control group may change
over time to become similar to the intervention in the
experimental group because of increased focus on treat-
ment of affective disorders (possibly also due to the
Danish HTA report [63]), the growing evidence of the
effect of combined intervention (pharmacologically and
psychologically) and because of a rub-off effect from the
many leading local clinicians involved in the allocation
of patients to the trials.
Even though there were very few exclusion criteria, it
is likely that patients who accept randomisation may be
a selected group and that patients with the most severe
illness, with comorbidity, e.g., substance abuse are
under-represented. Furthermore, the current design may
introduce attrition bias as the more severely ill and
patients with comorbid substance use problems and
other comorbidity may be more able and willing to
attend locally tailored treatment rather than centralised
treatment. Participants and eligible non-participants will
be compared using register-based variables to evaluate
whether participants in the trials are representative of
patients with affective disorders, discharged form their
first, second or third hospitalisation.
Advantages
Central randomisation protect against selection bias in
the randomisation process. Further, it is a major advan-
tage that the primary outcome measure, i.e., first re-
admission to a psychiatric ward can be obtained for all
included patients in the trials based on data from a
nation-wide health register data [72]. Data on outpatient
pharmacological treatment will be obtained from the
Medicinal Product Statistics that contains data on all
prescribed medication purchased nationwide at pharma-
cies from January 1, 1995 and onwards [87].
Generalisability
Pragmatic trials as the present trials are designed to
measure effectiveness; that is whether an intervention
works when used in usual conditions of care. To ensure
applicability in a wide range of usual care settings, prag-
matic trials should include all kinds of participants to
whom the intervention may be offered in the real world,
if its effectiveness is established [62]. A total of seven
psychiatric centres participated in our trials out of the 9
centres that offer acute hospitalisation in The Capital
Region of Denmark. The two non-participating centres
do not differ noticeably in patient population of affective
disorders or treatment services from the seven centres.
The trials include a moderately large number of patients
and have a naturalistic design with inclusion of patients
suffering from severe affective disorders with all kinds of
symptoms and comorbidities and with very few exclu-
sion criteria. Thus, patients with depressive, manic or
mixed index episodes, early and late onset, with or with-
out psychosis and comorbidity, such as personality dis-
orders, alcohol or substance abuse, etc, as well as
patients with poor or good treatment outcome during
hospitalisation were included. It should be noted that
participants were included in the trials based on the
diagnoses established by the treating medical doctors
employed at the psychiatric hospitals to obtain a high
generalisability of results from the trials to clinical set-
tings regarding patients with the most severe affective
disorders. Including only patients who fulfil diagnostic
criteria for an affective disorder according to a research-
based interview (such as, e.g., the SCAN interview) in
the trials would not mimic the naturalistic clinical set-
ting to which we wanted the results to be generalisable.
Nevertheless, the validity of diagnoses made by physi-
cians at discharge from psychiatric hospitals in Denmark
is reasonably high compared to research-based diagnos-
tic interviews with a probability of a correct diagnosis
for bipolar disorder of 94% [88] and with a probability
of a correct diagnosis for unipolar disorder of 83% [89].
Hospitalisation as an outcome has been criticised as
reductionistic. However, it benefits from being consis-
tently recorded and has high face validity as admission
to hospital reflects a serious relapse of the illness [90].
Nevertheless, it is possible that the decision to admit a
patient in our trials were influenced by the treating phy-
sicians’ attitude toward centralised and specialised treat-
ment although it is not evident that such attitudes may
cause bias. In the experimental group, physicians in the
mood disorder clinic may be reluctant to admit a
patient in order to increase the apparent benefits of the
mood disorder clinic or, in contrast, admit the patient
earlier and more often as these are followed more clo-
sely, which will make the experimental intervention look
worse. In the control group, the physicians may be
eager to admit a patient to prove the advantages of the
mood disorder clinic or, in contrast, be reluctant to
admit the patient to prove the benefits of standard care.
We are able to estimate the effect of such potential bias
by comparing diagnoses on severity of the illness leading
to hospitalisation (current depressive episode mild, mod-
erate or severe, current episode hypomanic or manic;
with or without psychotic symptoms) given by the inpa-
tient physicians at discharge from the outcome hospita-
lisation for the intervention and the control groups, as
these are recorded in the Danish Psychiatric Central
Register. The physicians at the psychiatric centre give
diagnoses independently of the referring outpatient phy-
sician. In addition, it is not clear that the potential effect
of such attitudes differs in the experimental trial setting
and the non-experimental everyday clinic. It should be
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should be considered in relation to other outcome mea-
sures such as the proportion with relapse and suicide in
the two groups of the trials. Notably, researchers did
not assess patients during the follow-up as the primary
outcome as well as one tertiary (suicide) outcome was
based on register data and other outcomes were based
on a questionnaire mailed to the participants. Using this
simple approach, the research team did not interact
with the patients in the trials in any way, i.e., the
research team had no effect on inclusion of participants
into the trials, delivered treatment or drop-out from
treatment, in contrast to what is the case in trials with
extensive and repeated assessment by researchers. Our
trials are thus designed to closely imitate the clinical
situation and results from the trials may be generalised
to patients discharged from early admissions with a
manic episode/bipolar disorder or a single moderate to
severe depressive episode or recurrent depressive disor-
der, respectively, and the results should be generalisable
into the everyday clinic.
The downside of this simple approach is that the sec-
ondary and most tertiary outcomes are based on
patient’s self-assessment that may have a decreased
validity, especially during manic episodes. We used the
Mood Disorder Questionnaire (MDQ) to assess the
development of a manic/mixed episode of at least mod-
erate severity although it is critical whether this is a reli-
able approach.
The health care system in The Capital Region of
Copenhagen is similar to the health care system else-
where in Denmark and to the majorities of Western
countries with a large primary health care system of
general practitioners and private specialists and a smal-
ler secondary health care sector including hospitals and
community psychiatric centres. Thus, we believe that
the results of the trials should be generalisable to most
Western communities.
Perspectives
The trials will evaluate the effect of a centralised and
specialised secondary care intervention early in the
course of severe affective disorder. Findings of a positive
effect should be interpreted with caution due to the lack
of blinding possibilities and further in combination with
results from economical evaluations. Nevertheless, pro-
viding evidence of a benefit of intensive outpatient inter-
ventions for patients early in the diseases of bipolar or
depressive disorder may have great influence on future
treatment for the patient groups. The perspective is to
be able to prevent some of the negative progression and
consequences of major affective disorders.
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